OncoTherapy Science, Inc. (TYO:4564)
Japan flag Japan · Delayed Price · Currency is JPY
15.00
0.00 (0.00%)
Nov 18, 2026, 10:29 AM JST

OncoTherapy Science Financials Overview

Millions JPY. Fiscal year is Apr - Mar.

Revenue & Profits

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
7128087506101,1341,153
Revenue Growth
-25.52%7.73%22.95%-46.21%-1.65%247.29%
Gross Profit
-609-521-503-855-676-1,617
Operating Income
-903-810-797-1,120-1,107-2,053
Net Income
-929-910-815-1,288-1,118-2,571
Earnings Per Share
-2.43-2.77-3.12-6.05-5.80-13.71
EPS Growth
------

Revenue by Segment

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cancer Precision Medicine Related Business
806.2747.06609.691,1261,155
Pharmaceutical Research and Development and Related Businesses
2.643.290.79.377.33
Unallocated Adjustment
-0.31-0.29-0.27-0.24-8.5
Total
808.53750.05610.121,1351,154

Cash & Debt

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Cash (Debt)
2,0832,0898335271,1171,836
Net Cash Growth
24.36%150.78%58.06%-52.82%-39.16%-36.67%
Net Cash Per Share
5.446.363.192.485.809.79
Cash & Investments
2,0832,0898335271,1171,836

Cash Flow & CapEx

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
-865-922-815-1,227-794-2,073
Capital Expenditures
-2-62--2-4-456
Free Cash Flow
-867-984-815-1,229-798-2,529
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
-85.53%-64.48%-67.07%-140.16%-59.61%-140.24%
Operating Margin
-126.83%-100.25%-106.27%-183.61%-97.62%-178.06%
Pretax Margin
-130.20%-112.38%-108.40%-210.82%-98.41%-222.90%
Profit Margin
-130.48%-112.62%-108.67%-211.15%-98.59%-222.98%
FCF Margin
-121.77%-121.78%-108.67%-201.47%-70.37%-219.34%

Valuation

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingNov '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Forward PE
-25.4925.4925.4925.4925.49
PS Ratio
8.609.9710.147.147.9811.53